Cargando…
Update on options for treatment of metastatic castration-resistant prostate cancer
BACKGROUND: Prostate cancer is one of the most common cancers in men in US and European countries. Despite having a favorable prognosis, the incidence of incurable metastatic disease and mortality in the US is about 28,000 per year. Although hormone-based androgen deprivation therapies typically res...
Autores principales: | Vishnu, Prakash, Tan, Winston W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895780/ https://www.ncbi.nlm.nih.gov/pubmed/20616956 |
Ejemplares similares
-
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014) -
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2021) -
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
por: Yehya, Amani, et al.
Publicado: (2022) -
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
por: Hatano, Koji, et al.
Publicado: (2023)